Seventure holds first close for Health for Life II

The fund follows its predecessor Health for Life Capital, which held its final close on €160m in 2015.

Investors
Health for Life Capital attracted strategic investments from Danone, Novartis, Lesaffre, Tornier, Unigrains and Bel. The new vehicle has attracted some investors from the first fund and new strategic industry partners, including a US based global food ingredient provider, and some institutional and entrepreneurial investors.

Investments
Investments can range from between €500,000-10m per round, or up to €20m per company. The fund is stage agnostic.

Following a similar strategy to its predecessor, Health for Life II will focus on the microbiome market, including companies involved in platforms, drugs, nutritional solutions, diagnostics and biomarkers. It can also invest in companies involved in digital therapeutics, connected health, digital nutritional advice, personalised nutrition, precision medicine and food technologies.

The fund will invest in companies globally, with a focus on Europe, North America, Israel and Asia.

Health for Life II has already committed to its first two investments: Axial Biotherapeutics in the US, and Galecto Biotech in Denmark.

People
Seventure Partners – Isabelle de Cremoux (CEO, managing partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Funds
• Venture
• France
• Healthcare
• Seventure (SPEF)
• France
• healthcare
• Venture